Company / Cash & Equivalents
uniQure N.V. Cash & Equivalents History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$158.9M
FY2024
5-year range
$158.9M / $556.3M
FY2020-FY2024
Trend
-34.2%
vs FY2023
Sector context
#112 of 207
Health Care
What the data says
At $159M, uniQure N.V.'s cash & equivalents ranks #112 of 207 in the Health Care sector. Cash & Equivalents has fluctuated over the past 10 years, ranging from $132M in FY2016 to $556M in FY2021.
Based on SEC 10-K filings.
$159M in FY2024 with a 5-year CAGR of -15.9%.
Declined from $228M to $159M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -34.1%
- 5-Year CAGR
- -15.9%
- 10-Year CAGR
- -
Sector benchmark
#112 of 207 in Health CareTop 54% of 207This company $158.9M Sector average $669.5M
▼
-76.3% below sector average
Key checks
Key Insights
- 5-year CAGR of -15.9%, indicating a declining trend.
- In FY2024, cash & equivalents decreased 34.2% year-over-year.
- Ranks #112 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -0.58 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $158.9M | -34.2% |
| FY2023 | $241.4M | +5.9% |
| FY2022 | $228.0M | -59.0% |
| FY2021 | $556.3M | +127.1% |
| FY2020 | $244.9M | -35.2% |
| FY2019 | $377.8M | +60.8% |
| FY2018 | $234.9M | +47.4% |
| FY2017 | $159.4M | +20.3% |
| FY2016 | $132.5M | -40.2% |
| FY2015 | $221.6M | +242.6% |
As of FY2024 · SEC Form 10-K · Last checked Jul 3, 2026